undamentalytics Newsletter
Sign in

Jazz Pharmaceuticals plc cash flow statement

In fiscal 2025, Jazz Pharmaceuticals plc's operations generated $1.36bn of cash; it spent $58.8m on capital projects, leaving free cash flow of $1.30bn. It returned $125m through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash from operations−16591522502884085325926937997769007791,2721,0921,3961,3561,692
Depreciation and amortisation110137101213151519273030334235
Stock-based pay68212345709299107102111121189222227248291296
Capital spending01161036361029204015282924385971
Free cash flow−16581502442783714965836647797368857511,2431,0681,3581,2971,622
Free cash flow after stock pay−22501302212343024044845576766267645621,0218411,1101,0061,326
Share buybacks——0013642622789952430114700270311125—
Shares issued75700——————————————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ELAN vs JAZZJAZZ vs OGNAMRX vs JAZZ

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Jazz Pharmaceuticals plc's SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Jazz Pharmaceuticals plc.